Literature DB >> 24142147

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.

Tomas Kalincik1, Vino Vivek, Vilija Jokubaitis, Jeannette Lechner-Scott, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Francois Grand'maison, Raymond Hupperts, Celia Oreja-Guevara, Roberto Bergamaschi, Gerardo Iuliano, Raed Alroughani, Vincent Van Pesch, Maria Pia Amato, Mark Slee, Freek Verheul, Ricardo Fernandez-Bolanos, Marcela Fiol, Daniele La Spitaleri, Edgardo Cristiano, Orla Gray, Jose Antonio Cabrera-Gomez, Vahid Shaygannejad, Joseph Herbert, Steve Vucic, Merilee Needham, Tatjana Petkovska-Boskova, Carmen-Adella Sirbu, Pierre Duquette, Marc Girard, Pierre Grammond, Cavit Boz, Giorgio Giuliani, Maria Edite Rio, Michael Barnett, Shlomo Flechter, Fraser Moore, Bhim Singhal, Elizabeth Alejandra Bacile, Maria Laura Saladino, Cameron Shaw, Eli Skromne, Dieter Poehlau, Norbert Vella, Timothy Spelman, Danny Liew, Trevor J Kilpatrick, Helmut Butzkueven.   

Abstract

The aim of this work was to evaluate sex differences in the incidence of multiple sclerosis relapses; assess the relationship between sex and primary progressive disease course; and compare effects of age and disease duration on relapse incidence. Annualized relapse rates were calculated using the MSBase registry. Patients with incomplete data or <1 year of follow-up were excluded. Patients with primary progressive multiple sclerosis were only included in the sex ratio analysis. Relapse incidences over 40 years of multiple sclerosis or 70 years of age were compared between females and males with Andersen-Gill and Tweedie models. Female-to-male ratios stratified by annual relapse count were evaluated across disease duration and patient age and compared between relapse-onset and primary progressive multiple sclerosis. The study cohort consisted of 11 570 eligible patients with relapse-onset and 881 patients with primary progressive multiple sclerosis. Among the relapse-onset patients (82 552 patient-years), 48,362 relapses were recorded. Relapse frequency was 17.7% higher in females compared with males. Within the initial 5 years, the female-to-male ratio increased from 2.3:1 to 3.3:1 in patients with 0 versus ≥4 relapses per year, respectively. The magnitude of this sex effect increased at longer disease duration and older age (P < 10(-12)). However, the female-to-male ratio in patients with relapse-onset multiple sclerosis and zero relapses in any given year was double that of the patients with primary progressive multiple sclerosis. Patient age was a more important determinant of decline in relapse incidence than disease duration (P < 10(-12)). Females are predisposed to higher relapse activity than males. However, this difference does not explain the markedly lower female-to-male sex ratio in primary progressive multiple sclerosis. Decline in relapse activity over time is more closely related to patient age than disease duration.

Entities:  

Keywords:  MSBase; multiple sclerosis; prediction; risk factors; sex

Mesh:

Year:  2013        PMID: 24142147     DOI: 10.1093/brain/awt281

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  42 in total

Review 1.  Pregnancy, postpartum and parity: Resilience and vulnerability in brain health and disease.

Authors:  Nicholas P Deems; Benedetta Leuner
Journal:  Front Neuroendocrinol       Date:  2020-01-24       Impact factor: 8.606

Review 2.  Do Microglial Sex Differences Contribute to Sex Differences in Neurodegenerative Diseases?

Authors:  Lay Kodama; Li Gan
Journal:  Trends Mol Med       Date:  2019-06-03       Impact factor: 11.951

3.  Ovarian aging is associated with gray matter volume and disability in women with MS.

Authors:  Jennifer S Graves; Roland G Henry; Bruce A C Cree; Geralyn Lambert-Messerlian; Ruth M Greenblatt; Emmanuelle Waubant; Marcelle I Cedars; Alyssa Zhu; Peter Bacchetti; Stephen L Hauser; Jorge R Oksenberg
Journal:  Neurology       Date:  2017-12-22       Impact factor: 9.910

4.  Differentiating societal costs of disability worsening in multiple sclerosis.

Authors:  Nils-Henning Ness; Dirk Schriefer; Rocco Haase; Benjamin Ettle; Christian Cornelissen; Tjalf Ziemssen
Journal:  J Neurol       Date:  2019-12-17       Impact factor: 4.849

Review 5.  The importance of studying sex differences in disease: The example of multiple sclerosis.

Authors:  Lisa C Golden; Rhonda Voskuhl
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

6.  Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.

Authors:  Rhonda R Voskuhl; Amr H Sawalha; Yuichiro Itoh
Journal:  Mult Scler       Date:  2018-01       Impact factor: 6.312

Review 7.  Genotype and Phenotype in Multiple Sclerosis-Potential for Disease Course Prediction?

Authors:  Vilija G Jokubaitis; Yuan Zhou; Helmut Butzkueven; Bruce V Taylor
Journal:  Curr Treat Options Neurol       Date:  2018-04-24       Impact factor: 3.598

8.  Sex-specific differences in rim appearance of multiple sclerosis lesions on quantitative susceptibility mapping.

Authors:  Tolaymat B; Zheng W; Chen H; Choi S; Li X; Harrison Dm
Journal:  Mult Scler Relat Disord       Date:  2020-06-18       Impact factor: 4.339

9.  The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Authors:  Helen Tedeholm; Bengt Skoog; Vera Lisovskaja; Björn Runmarker; Olle Nerman; Oluf Andersen
Journal:  J Neurol       Date:  2015-02-26       Impact factor: 4.849

10.  Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.

Authors:  Ana Paula Kallaur; Edna Maria Vissoci Reiche; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Wildea Lice de Carvalho Jennings Pereira; Daniela Frizon Alfieri; Tamires Flauzino; Caio de Meleck Proença; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.